Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide

Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide

Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, alpha-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when inject...

Brain glucose utilization can be increased by administering an agent that improves central nervous system insulin sensivity. By improving the central nervous system insulin sensivity and increasing brain glucose utilization, age-related memory loss and dementia can be prevented and/or reduced. The improvement in brain glucose utilization is independent of treatment for Type II diabetes. Among the central nervous system insulin sensitizers that can be administered to increase brain glucose utiliz...

Brain glucose utilization can be increased by administering an agent that improves central nervous system insulin sensivity. By improving the central nervous system insulin sensivity and increasing brain glucose utilization, a ge- related memory loss and dementia can be prevented and/or reduced. The improvement in brain glucose utilization is independent of treatment for Typ e II diabetes. Among the central nervous system insulin sensitizers that can b e administered to increase brain glucose ut...

An oral medicament having delayed release comprises a therapeutically effective amine absorbed (ionically bound) on a cross-linked sulphonic acid cation exchange resin, including phenol- and carboxylic-sulphonic acid cation exchange resins. Conventional excipients may be included in compositions to be administered as capsules, pills, powders, syrups or emulsions. The cross linkage of the resin is between 3 and 17% and the particle size is between 10 and 80 mesh. Sulphonated polymerizates of poly...